// App-Quantinova.ai

SA-OR20 : Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER): Results in the Prespecified Subgroup with Diabetes

Researchers

Presenter

  • Agarwal Rajiv

Principal Investigators

  • Rossignol Patrick

  • Arthur Susan

  • Conrad Ansgar

  • White William B

  • Williams Bryan

Medical Centers

  • IU School of Medicine, Indianapolis, Indiana, United States

  • University of Lorraine and FCRIN INI-CRCT, Nancy, France

  • Relypsa Inc. a Vifor Pharma Group Company Redwood City California United States

  • University of Connecticut School of Medicine, Farmington, Connecticut, United States

  • Kings College London, London, United Kingdom

Locations

  • United States

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Hypertension

  • Diabetes

  • Resistant hypertension

Biomarkers

  • N/A

Drug/Treatment

  • Spironolactone

  • Patiromer

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved